UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 6, 2007
MOLECULAR INSIGHT PHARMACEUTICALS, INC.
(Exact Name of Registrant as Specified in Charter)
| | | | | |
| Massachusetts | | 001-33284 | | 04-0562086 |
(State or Other Jurisdiction
of Incorporation) | | (Commission
File Number) | | (IRS Employer
Identification No.) |
160 Second Street, Cambridge, Massachusetts 02142
(Address of Principal Executive Offices, Including Zip Code)
(617) 492-5554
(Registrant’s Telephone Number, Including Area Code)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (seeGeneral Instruction A.2. below):
o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
TABLE OF CONTENTS
Item 8.01. Other Events.
On August 6, 2007, Molecular Insight Pharmaceuticals, Inc. issued a press release announcing that a study on results from the Zemiva (iodofiltic acid I 123 or BMIPP) Phase 2b clinical trial has been accepted as an oral, late breaking presentation at the upcoming annual meeting of the American Society of Nuclear Cardiology (ASNC).
The description of the press release set forth herein does not purport to be complete and is qualified in its entirety by reference to the full text of the press release attached hereto as Exhibit 99.1 and incorporated herein by reference.
Item 9.01. Financial Statements and Exhibits.
| | (d) | | Exhibits. The following exhibit is being filed herewith: |
| | 99.1 | | Press Release of Molecular Insight Pharmaceuticals, Inc., issued August 6, 2007. |
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this Report to be signed on its behalf by the undersigned, hereunto duly authorized, on the 6th day of August, 2007.
| | | | | |
| | MOLECULAR INSIGHT PHARMACEUTICALS, INC.
| |
| | By: | /s/ Priscilla Harlan | |
| | | Name: | Priscilla Harlan | |
| | | Title: | Vice President,
Corporate Communications & Investor Relations |
| |
Exhibit Index to Current Report on Form 8-K
Dated August 6, 2007
| | | |
| Exhibit | | |
| Number | | |
| | | |
| 99.1 | | Press Release of Molecular Insight Pharmaceuticals, Inc., issued August 6, 2007. |
